title: [Significance of the antimicrobial drug used to prevent febrile infection following prostate needle biopsy].
abstract: The rate of incidence of febrile infection and the antimicrobial drug used at the time of prostate needle biopsy was examined retrospectively. SPFX (sparfloxacin) 400 mg (January 2007 to March 2010) and LVFX (levofloxacin) 500 mg (April 2010, onward) were administered prophylactically in 1,034 patients undergoing transrectal or transperineal prostate biopsy. One febrile infection occurred and resolved in each group. A single dose of LVFX 500 mg before the procedure effectively prevented febrile infection in both transrectal and transperineal prostate needle biopsy.
authors.affiliation: The Department of Urology, National Kyushu Medical Center.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.affiliation: The Department of Urology, National Kyushu Medical Center.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Maki
authors.affiliation: The Department of Urology, National Kyushu Medical Center.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: The Department of Urology, National Kyushu Medical Center・The Department of Clinical Research Institute, National Kyushu Medical Center.
authors.forename: Masumitsu
authors.initials: M
authors.lastname: Hamaguchi
authors.affiliation: The Department of Urology, National Kyushu Medical Center・The Department of Clinical Research Institute, National Kyushu Medical Center.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshikawa
authors.affiliation: The Department of Urology, National Kyushu Medical Center・The Department of Clinical Research Institute, National Kyushu Medical Center.
authors.forename: Naotaka
authors.initials: N
authors.lastname: Sakamoto
authors.affiliation: The Department of Urology, National Kyushu Medical Center・The Department of Clinical Research Institute, National Kyushu Medical Center.
authors.forename: Atushi
authors.initials: A
authors.lastname: Iguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001707:Biopsy, Needle / Q000009:adverse effects*; D005334:Fever / Q000517:prevention & control; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D017053:Infection Control / Q000379:methods*; D064704:Levofloxacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D012189:Retrospective Studies; D013308:Streptonigrin
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C079133:retrostatin; D013308:Streptonigrin; D064704:Levofloxacin; C061363:sparfloxacin